PANCREOX

NCT00536874 📎

Regimen

Experimental
mFOLFOX6: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + 5-FU 400 mg/m2 bolus + 2400 mg/m2 46h infusion q2w.
Control
Infusional 5-FU + leucovorin q2w.

Population

Advanced PDAC with progression on prior gemcitabine-based therapy, ECOG 0-2, Canadian multicenter.

Key finding

PANCREOX is the puzzling inverse mirror of CONKO-003: adding oxaliplatin to 5-FU/LV showed no PFS benefit and a detrimental OS effect in 2L metastatic PDAC. Hypotheses include imbalanced post-progression therapy and small N (108). The conflict with CONKO-003 prevents oxaliplatin-based 2L from being a category 1 recommendation.

Source: PMID 27621395

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.96)